Capital Increase in Genmab as a Result of Employee Warrant Exercise
27 Februar 2024 - 9:40PM
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
COPENHAGEN, Denmark; February 27, 2024 –
Genmab A/S (Nasdaq: GMAB) will increase
its share capital by 48,429 shares as a consequence of the exercise
of employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
7,325 shares at DKK 1,025.00,19,631 shares at DKK 1,032.00,2,473
shares at DKK 1,050.00,1,422 shares at DKK 1,161.00,40 shares at
DKK 1,334.50,1,036 shares at DKK 1,362.50,6,660 shares at DKK
1,402.00,129 shares at DKK 1,408.00, and9,713 shares at DKK
1,615.00.
Proceeds to the company are approximately DKK 58.7 million. The
increase corresponds to approximately 0.07% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 41
of January 13, 2023, it is hereby announced, that the total nominal
value of Genmab A/S' share capital after the capital increase is
DKK 66,122,964 which is made up of 66,122,964 shares of a nominal
value of DKK 1 each, corresponding to 66,122,964 votes.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For more than
20 years, its passionate, innovative and collaborative team has
invented next-generation antibody technology platforms and
leveraged translational research and data sciences, which has
resulted in a proprietary pipeline including bispecific T-cell
engagers, next-generation immune checkpoint modulators, effector
function enhanced antibodies and antibody-drug conjugates. To help
develop and deliver novel antibody therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. By 2030, Genmab’s vision is to transform
the lives of people with cancer and other serious diseases with
Knock-Your-Socks-Off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com and follow us on X.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications &
Corporate AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements.
The words “believe,” “expect,” “anticipate,” “intend” and “plan”
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab’s most recent financial reports, which are
available on www.genmab.com and the risk factors included in
Genmab’s most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. Genmab does not undertake any obligation
to update or revise forward looking statements in this Company
Announcement nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law. Genmab A/S and/or its
subsidiaries own the following trademarks: Genmab®; the Y-shaped
Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
Company Announcement no. 12 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 270224_CA12 Warrant Exercise
Genmab AS (TG:GE9)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Genmab AS (TG:GE9)
Historical Stock Chart
Von Jun 2023 bis Jun 2024